Drug intelligence / Profile preview

FHND71

Development stage: Unknown
Lead developer: Protheragen
Modality: Small Molecules
Administration: Oral

Overview

FHND71 is a small molecule inhibitor of the RET (Rearranged during Transfection) receptor tyrosine kinase, currently under development by Protheragen. RET is a proto-oncogene that, when activated by mutations or chromosomal rearrangements, drives the progression of various cancers, including medullary thyroid cancer and RET fusion-positive non-small cell lung cancer. FHND71 is designed to selectively inhibit the kinase activity of RET, thereby blocking downstream signaling pathways such as RAS/MAPK and PI3K/AKT that promote tumor cell growth, survival, and metastasis. The compound is currently being evaluated in Phase I clinical trials for the treatment of patients with advanced solid tumors harboring RET alterations.

Other names: FHND71FHND-71FHND 71

Targets

RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on FHND71.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FHND71.

Explore the full profile